ProCE Banner Activity

Screening for Alpha-1 Antitrypsin Deficiency Liver Disease: Call to Action

Clinical Thought

Alpha-1 antitrypsin deficiency is primarily known for its impact on lung health, but its impact on the liver is highly underrecognized and poorly understood. In this commentary, an expert hepatologist discusses the importance of screening for AATD in those with lung and liver symptoms, even in the setting of confirmed diagnosis of other conditions, and in those with a family history.

Released: August 28, 2024

Expiration: August 27, 2025

Share

Faculty

Pavel Strnad

Pavel Strnad, MD

Full Professor
Department of Internal Medicine III
University Hospital Aachen
Aachen, Germany

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Takeda Development Center Americas, Inc.

Takeda Development Center Americas, Inc.

Disclosure

Primary Author

Pavel Strnad, MD

Full Professor
Department of Internal Medicine III
University Hospital Aachen
Aachen, Germany

Pavel Strnad, MD: researcher: Arrowhead Pharmaceuticals, CSL Behring; consultant/advisor/speaker: BioMarin, BridgeBio, CSL Behring, GlaxoSmithKline, Intellia, Novo Nordisk, Takeda.